关注
Maurizio Zazzi
Maurizio Zazzi
Professor of Microbiology, University of Siena
在 unisi.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
AMJ Wensing, DA Van De Vijver, G Angarano, B Åsjö, C Balotta, E Boeri, ...
The Journal of infectious diseases 192 (6), 958-966, 2005
5582005
European guidelines on the clinical management of HIV-1 tropism testing
LPR Vandekerckhove, AMJ Wensing, R Kaiser, F Brun-Vézinet, B Clotet, ...
The Lancet infectious diseases 11 (5), 394-407, 2011
3142011
Beyond sparsity: Tree regularization of deep models for interpretability
M Wu, M Hughes, S Parbhoo, M Zazzi, V Roth, F Doshi-Velez
Proceedings of the AAAI conference on artificial intelligence 32 (1), 2018
3062018
Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe
LM Hofstra, N Sauvageot, J Albert, I Alexiev, F Garcia, D Struck, ...
Clinical infectious diseases 62 (5), 655-663, 2016
1872016
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
D Paraskevis, O Pybus, G Magiorkinis, A Hatzakis, AMJ Wensing, ...
Retrovirology 6, 1-11, 2009
1542009
A novel methodology for large-scale phylogeny partition
MCF Prosperi, M Ciccozzi, I Fanti, F Saladini, M Pecorari, V Borghi, ...
Nature communications 2 (1), 321, 2011
1382011
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
DA Van De Vijver, AMJ Wensing, G Angarano, B Åsjö, C Balotta, E Boeri, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 41 (3), 352-360, 2006
1362006
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples
G Venturi, M Catucci, L Romano, P Corsi, F Leoncini, PE Valensin, ...
The Journal of infectious diseases 181 (2), 740-745, 2000
1282000
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
I Vicenti, M Zazzi, F Saladini
Expert Opinion on Therapeutic Patents 31 (4), 325-337, 2021
1202021
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents
A Brai, R Fazi, C Tintori, C Zamperini, F Bugli, M Sanguinetti, E Stigliano, ...
Proceedings of the National Academy of Sciences 113 (19), 5388-5393, 2016
1182016
The development of artificial neural networks to predict virological response to combination HIV therapy
B Larder, D Wang, A Revell, J Montaner, R Harrigan, F De Wolf, J Lange, ...
Antiviral therapy 12 (1), 15-24, 2007
972007
Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens
A Marconi, M Balestrieri, G Comastri, FR Pulvirenti, W Gennari, ...
Clinical microbiology and infection 15 (1), 93-97, 2009
932009
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe
A De Luca, D Dunn, M Zazzi, R Camacho, C Torti, I Fanti, R Kaiser, ...
The Journal of infectious diseases 207 (8), 1216-1220, 2013
892013
Clinically validated genotype analysis: guiding principles and statistical concerns
F Brun-Vezinet, D Costagliola, MA Khaled, V Calvez, F Clavel, B Clotet, ...
Antiviral therapy 9 (4), 465-478, 2004
892004
New findings in HCV genotype distribution in selected West European, Russian and Israeli regions
V Kartashev, M Döring, L Nieto, E Coletta, R Kaiser, S Sierra, A Guerrero, ...
Journal of Clinical Virology 81, 82-89, 2016
882016
Selecting anti-HIV therapies based on a variety of genomic and clinical factors
M Rosen-Zvi, A Altmann, M Prosperi, E Aharoni, H Neuvirth, ...
Bioinformatics 24 (13), i399-i406, 2008
852008
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time
D Frentz, CAB Boucher, M Assel, A De Luca, M Fabbiani, F Incardona, ...
PloS one 5 (7), e11505, 2010
832010
Combining kernel and model based learning for HIV therapy selection
S Parbhoo, J Bogojeska, M Zazzi, V Roth, F Doshi-Velez
AMIA Summits on Translational Science Proceedings 2017, 239, 2017
822017
Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge
F Picarazzi, I Vicenti, F Saladini, M Zazzi, M Mori
Molecules 25 (23), 5695, 2020
802020
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with …
R Gagliardini, A Ciccullo, A Borghetti, F Maggiolo, D Bartolozzi, V Borghi, ...
Open forum infectious diseases 5 (6), ofy113, 2018
792018
系统目前无法执行此操作,请稍后再试。
文章 1–20